Computational Prediction and In Vitro Validation of Potential Molecular Targets Associated with Adverse Reactions of

Xiaojuan He1, Rui Jing1, Na Wu1

  • 1Department of Neurosurgery, Affiliated Hospital of Hebei Engineering University, Handan, People's Republic of China.

Insights

Neonatal antimicrobial drugs can cause adverse reactions by inhibiting off-target proteins like AKR1B1 and Neprilysin. This study reveals molecular targets, aiding safer drug development for infants.

Area of Science:

  • Pharmacology and Toxicology
  • Computational Chemistry
  • Neonatal Medicine

Background:

  • Neonates exhibit heightened susceptibility to adverse drug reactions (ADRs) from antimicrobials, impacting long-term health.
  • Common ADRs include allergic reactions, gastrointestinal issues, and hepatic/renal dysfunction.
  • Understanding the molecular basis of these ADRs is crucial for neonatal patient safety.

Purpose of the Study:

  • To identify common molecular off-targets of frequently used neonatal antimicrobial drugs.
  • To investigate the binding mechanisms and stability of drug-off-target interactions using computational methods.
  • To experimentally validate the inhibitory effects of these drugs on identified off-targets.

Main Methods:

  • Reverse target identification using DrugBank and SwissTargetPrediction.
  • Venn diagram analysis to pinpoint common potential drug targets.
  • Molecular docking and molecular dynamics (MD) simulations to assess drug-target interactions.
  • In vitro bioactivity assays to determine inhibitory concentrations (IC50).

Main Results:

  • AKR1B1 and Neprilysin were identified as common potential off-targets for selected antimicrobial drugs.
  • In vitro assays confirmed significant inhibitory activity of these drugs against AKR1B1 and Neprilysin, with IC50 values in the micromolar range.
  • MD simulations demonstrated stable drug-protein complexes and identified key interactions, including hydrogen bonds.

Conclusions:

  • Antimicrobial drugs used in neonates may exert adverse effects by inhibiting specific off-target proteins, namely AKR1B1 and Neprilysin.
  • This research provides critical molecular insights into neonatal antimicrobial ADR mechanisms.
  • Findings support the rational design of safer antimicrobial analogs and inform future neonatal pharmacotherapy research.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
391
Automated Microbial Diagnostics01:24

Automated Microbial Diagnostics

Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...
50
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94